Bengaluru: Strides Pharma Science Limited announced that its wholly owned subsidiary, Strides Pharma Global Pte Ltd, Singapore, has received approval for normal version Of Sucralfate Oral Suspension1 g/10 mL, from the United States Food and Drug Administration (US FDA).

This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD). carafe 1 gram/10 ml AbbVie, Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis and stomach inflammation, and to prevent stress ulcers.

Sucralfate Oral Suspension, 1 g/10 mL market size is $124 million according to IQVIA (March 2024). Sucralfate Oral Suspension, 1 g/10 mL will be manufactured at the company’s flagship facility at KRS Garden in Bangalore, India.